Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 2/20 | 0.37 |
| ▸ | LTA4H | P09960 | 5/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.35 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.35 |
| ▸ | VNN1 | O95497 | 3/20 | 0.34 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.34 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL876023 | 0.90 | KCNH2 (0.39) | PLA2G7KCNH2HTR2ASLC6A4CDK8 | |
| SCHEMBL9900810 | 0.89 | BRAF (0.43) | PLA2G7SMN1; SMN2SCN9A | |
| SCHEMBL14656218 | 0.85 | TRPA1 (0.40) | KCNH2LTA4HSMN1; SMN2 | |
| SCHEMBL9904726 | 0.82 | THRB (0.39) | PLA2G7KCNH2HTR2ASLC6A4CDK8 | |
| SCHEMBL9923488 | 0.81 | PLA2G7 (0.35) | PLA2G7KCNH2HTR2ASLC6A4CDK8 | |
| SCHEMBL9905023 | 0.79 | POLB (0.41) | PLA2G7KCNH2HTR2ASLC6A4LTA4H | |
| SCHEMBL875283 | 0.79 | BRAF (0.44) | PLA2G7SMN1; SMN2SCN9A | |
| SCHEMBL9923491 | 0.79 | HTR2A (0.37) | PLA2G7KCNH2HTR2ASLC6A4SMN1; SMN2 | |
| SCHEMBL9900872 | 0.78 | HTR2A (0.39) | PLA2G7KCNH2HTR2ASLC6A4SMN1; SMN2 | |
| SCHEMBL9900889 | 0.77 | KCNH2 (0.39) | PLA2G7KCNH2HTR2ASLC6A4CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859573-B2 | Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| US-8859573-B2 | Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| US-8859573-B2 | Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-10-14 | — | — | US | disclosed |
| EP-2649050-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-20130252986-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252986-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252986-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| WO-2012075917-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252986-A1 | COMPOUNDS | LIPG, ENPP2, PLA2G1B | PLA2G7 6/4885KCNH2 4023/4885HTR2A 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.